Zenas BioPharma Statistics

Total Valuation

Zenas BioPharma has a market cap or net worth of $327.22 million. The enterprise value is -$59.19 million.

Market Cap	327.22M
Enterprise Value	-59.19M

Important Dates

The next estimated earnings date is Tuesday, March 4, 2025, before market open.

Earnings Date	Mar 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Zenas BioPharma has 41.79 million shares outstanding. The number of shares has increased by 103.87% in one year.

Current Share Class	41.79M
Shares Outstanding	41.79M
Shares Change (YoY)	+103.87%
Shares Change (QoQ)	+391.15%
Owned by Insiders (%)	0.91%
Owned by Institutions (%)	58.98%
Float	23.09M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.91
P/TBV Ratio	0.91
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.95, with a Debt / Equity ratio of 0.00.

Current Ratio	8.95
Quick Ratio	8.79
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -63.33% and return on invested capital (ROIC) is -38.80%.

Return on Equity (ROE)	-63.33%
Return on Assets (ROA)	-34.13%
Return on Invested Capital (ROIC)	-38.80%
Return on Capital Employed (ROCE)	-37.01%
Revenue Per Employee	n/a
Profits Per Employee	-$1.13M
Employee Count	114
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Zenas BioPharma has paid $301,000 in taxes.

Income Tax	301,000
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	8.38
200-Day Moving Average	n/a
Relative Strength Index (RSI)	50.31
Average Volume (20 Days)	207,021

Short Selling Information

The latest short interest is 3.30 million, so 7.89% of the outstanding shares have been sold short.

Short Interest	3.30M
Short Previous Month	3.34M
Short % of Shares Out	7.89%
Short % of Float	14.29%
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-110.40M
Operating Income	-133.04M
Pretax Income	-54.46M
Net Income	-128.97M
EBITDA	-132.91M
EBIT	-133.04M
Earnings Per Share (EPS)	-$41.59

Full Income Statement

Balance Sheet

The company has $386.80 million in cash and $384,000 in debt, giving a net cash position of $386.42 million or $9.25 per share.

Cash & Cash Equivalents	386.80M
Total Debt	384,000
Net Cash	386.42M
Net Cash Per Share	$9.25
Equity (Book Value)	359.44M
Book Value Per Share	8.60
Working Capital	349.78M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$96.52 million and capital expenditures -$74,000, giving a free cash flow of -$96.59 million.

Operating Cash Flow	-96.52M
Capital Expenditures	-74,000
Free Cash Flow	-96.59M
FCF Per Share	-$2.31

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Zenas BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-103.87%
Shareholder Yield	-103.87%
Earnings Yield	-39.41%
FCF Yield	-29.52%

Dividend Details

Analyst Forecast

The average price target for Zenas BioPharma is $29.20, which is 272.93% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$29.20
Price Target Difference	272.93%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zenas BioPharma has an Altman Z-Score of 8.55 and a Piotroski F-Score of 2.

Altman Z-Score	8.55
Piotroski F-Score	2